Impact of SARS-CoV-2 on lung cancer patient under immunotherapy

Patients with lung cancer have an increased vulnerability to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection, and the association of the two diseases increases the severity of the infection. We present the case of a patient aged 72 years, a former 30 pack year (PA) smoker with 12 years withdrawal, and unvaccinated anti-SARS-CoV-2, with GOLD 2 COPD, hypertensive, recently diagnosed with left bronchopulmonary neoplasm and under immunotherapy. The patient had a fast-evolving SARS-COVID infection to a critical form, complicated with acute pulmonary embolism, nosocomial fungal infection, myelodysplastic syndrome, moderate multifactorial anaemic syndrome and heart disease. The unfavourable evolution of the patient’s condition led to the temporary suspension of oncological treatment throughout the critical period, but without the progression of neoplastic disease. Although bronchopulmonary neoplasm emphasises the severity of SARS-CoV-2 infection, it is not mandatory to develop a harmful oncologic outcome without proper treatment, especially immunotherapy.